Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Accelerated Approval after Bracelet-1

<< Previous

Bullboard Posts

Next >>

Comment by SundayMovieson Dec 05, 2022 1:44pm

155 Views

Post# 35151478

RE:RE:RE:RE:RE:RE:RE:RE:RE:Accelerated Approval after Bracelet-1

Yes, I am talking about AstraZeneca and yes a lowball hostile takeover. They did this before:

Growth will come from cutting-edge technologies that harness patients’ own immune systems to fight cancer as well as targeted treatments that can help eliminate the need for standard chemotherapy, Fredrickson said. Recent successes include Enhertu, a breast cancer therapy acquired via a $6.9 billion partnership reached in 2019 with Japanese developer Daiichi Sankyo Co.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects